Skip to main content
S 2691 115th Congress Senate Health Business ethics Business expenses Business records Child health Civil actions and liability Corporate finance and management Department of Health and Human Services Department of Justice Department of Labor Drug safety, medical device, and laboratory regulation Drug trafficking and controlled substances Drug, alcohol, tobacco use Education programs funding Elementary and secondary education Employment taxes Executive agency funding and structure Government information and archives Government studies and investigations Government trust funds

Opioid Crisis Accountability Act of 2018

Introduced: April 17, 2018 Introduced by: Sanders, Bernard Independent · Vermont See on congress.gov
Sign in to write a letter Sign in to watch
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Apr 17, 2018
Read twice and referred to the Committee on Finance.
Apr 17, 2018
Introduced in Senate
 Plain-English summary Congressional Research Service

Opioid Crisis Accountability Act of 2018

This bill amends the Federal Food, Drug, and Cosmetic Act to prohibit a drug manufacturer from engaging in illegal marketing and distribution practices, including falsely advertising, promoting, or marketing that an opioid has no addiction-forming or addiction-sustaining qualities or risks.

The bill penalizes drug manufacturers or distributors who illegally advertise, market or distribute an opioid product, including by (1) imposing a civil fine or salary confiscation, (2) revoking any remaining period of market exclusivity for such product, (3) requiring reimbursement of federal funding received for such product, and (4) prohibiting certain tax credits.

What's happening now April 17, 2018

Read twice and referred to the Committee on Finance.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Democratic 2